Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

PD-L1/CD80 cis Interactions Disrupt PD-L1–PD-1 Binding and Promote T-cell Function

DOI: 10.1158/2159-8290.CD-RW2019-075 Published July 2019
  • Article
  • Info & Metrics
Loading
  • Major finding: Binding of PD-L1 to CD80 in cis disrupts its binding to PD-1 and restricts PD-1–mediated T-cell suppression.

  • Concept: Knock-in mice with mutated PD-L1 or CD80 exhibited impaired PD-L1/CD80 binding and reduced T-cell function.

  • Impact: Targeting cis-PD-L1/CD80 interactions might provide new therapeutic approaches for cancer.

Immunotherapy based on targeting immune checkpoint receptors such as PD-1 and CTLA4 has shown clinical benefit in several types of cancer. Blocking these inhibitors enables the activation of tumor-specific T cells, though it can also lead to the activation of autoreactive T cells. PD-1 interaction with either PD-L1 or PD-L2 promotes T-cell inhibition. CTLA4 interaction can lead to inhibition of T cells through binding to CD80 or CD86, whereas CD80 and CD86 can activate T cells through binding to the costimulatory protein CD28. Interactions between PD-L1 and CD80 have also been reported, but the outcome of these interactions is not well defined. Sugiura and colleagues investigated the cis (within the same cell) and trans (between T cells and antigen-presenting cells such as dendritic cells) interactions of checkpoint inhibitory molecules and found that CD80 interacts in cis with PD-L1 on primary activated dendritic cells. This interaction impaired binding of PD-L1 to PD-1 and subsequently abrogated PD-1–mediated T-cell suppression in both mice and human orthologs. The interaction of CD80 with PD-L1 did not interfere with binding of CD80 to CD28 or CTLA4. Mice with knock-in mutations in PD-L1 or CD80 that prevented cis interactions showed impaired PD-L1/CD80 interaction and defective T-cell responses as shown by reduced T-cell production of IFNγ and IL2 following antigen stimulation. Initiation of antitumor immune response was also attenuated when CD80/PD-L1 cis interactions were disrupted. Mutated mice also showed reduced T-cell function in an autoimmunity model. Collectively, these results indicate that cis PD-L1/CD80 interactions prevent PD-L1/PD-1 interaction and promote T-cell responses against foreign, tumor-associated, and self antigens. These results show how optimal T-cell responses are regulated by costimulatory and coinhibitory signals and provide insights that might guide optimization of immune checkpoint blockade therapy.

Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 2019;364:558–66.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 9 (7)
July 2019
Volume 9, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PD-L1/CD80 cis Interactions Disrupt PD-L1–PD-1 Binding and Promote T-cell Function
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
PD-L1/CD80 cis Interactions Disrupt PD-L1–PD-1 Binding and Promote T-cell Function
Cancer Discov July 1 2019 (9) (7) OF10; DOI: 10.1158/2159-8290.CD-RW2019-075

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PD-L1/CD80 cis Interactions Disrupt PD-L1–PD-1 Binding and Promote T-cell Function
Cancer Discov July 1 2019 (9) (7) OF10; DOI: 10.1158/2159-8290.CD-RW2019-075
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • T-cell Receptor–Engineered T Cells Show Efficacy in HPV+ Carcinomas
  • Germline Genetic Variation Modulates Tumor Immune Microenvironment
  • Computational Analysis Finds Protein Stability–Related Cancer Mutations
Show more Research Watch

Immunology

  • NK Cells Mediate T-cell Inflammation in the Tumor Microenvironment
  • MEK Inhibition Acts on CD8+ T Cells to Enhance Antitumor Immunity
  • HPV Antigen–Specific B Cells in Tumor Microenvironment Characterized
Show more Immunology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement